Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details)

v3.7.0.1
Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Business Combinations [Abstract]        
Revenue $ 411 $ 435
Net loss (3,311) (3,223) (6,941) (8,051)
Net loss: Non-controlling interest (91) (145) (219) (339)
Net loss attributable to Heat Biologics, Inc. $ (3,220) $ (3,078) $ (6,722) $ (7,712)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.09) $ (0.17) $ (0.21) $ (0.77)